Phase 1 Study of ADX-626 in Healthy Participants

Recruiting Status: Recruiting Age: 18 – 45 Years Old This first-in-human study will evaluate the safety and tolerability of ADX-626 in healthy participants. The study will also look at how ADX-626 interacts with the human body (the pharmacokinetics and pharmacodynamics of ADX-626). Learn More

The release as fetched from its publisher. adarx.com ↗